PREDICTING THE RISK OF PROTHROMBOTIC CHANGES IN ADOLESCENTS WITH ESSENTIAL HYPERTENSION

Today, the problem of early diagnosis of hematological changes predisposing to the development of thrombotic complications in patients with essential hypertension (EH) is an urgent problem that requires close attention not only of physicians, but also of pediatricians. The aim of the study was the development of prognostic criteria for risk of prothrombotic changes (PC) in adolescents with EH, timely preventive measures and prevention of thrombotic complications. Sixty adolescents with EH without PC and 37 adolescents with EH and PC were examined. We used the following methods: clinical anamnestic (including genealogy), functional and ultrasound, laboratory, mathematical and statistical. To create a mathematical model of forecasting, discriminant analysis was used, with the help of which from the 59 proposed predictors the algorithm selected 8 most informative features: the C777T polymorphism of the 5,10-methylenetetrahydrofolate reductase gene, the A66G gene of the methionine synthase reductase gene, the daily diastolic blood pressure level, the level of the nocturnal systolic arterial pressure-time index of hypertension, systolic blood pressure during the day, weighed down by thrombotic genealogically history, early onset of thrombosis, burdened thrombotic genealogical history. Our method for predicting the risk of developing PC allows to place adolescents with EH having an increased risk of developing these coagulation shifts in a separate group, to identify thrombogenic risk in adolescence and, if necessary, to initiate preventive measures in time to reduce the incidence of thrombotic complications of EH and mortality of patients.

adolescents, genes, essential hypertension, prothrombotic changes, thrombosis

1. ВОЗ. Сердечно-сосудистые заболевания. Информационный бюллетень № 317. - 2015 г. - Режим доступа: http://www.who.int/mediacentre/factsheets/ fs317/ru/ (дата обращения: 7.04.2017)

2. Долгих В.В., Большакова С.Е., Филиппов Е.С., Гомелля М.В. Изменчивость генов фолатного циклау детей с эссенциальной артериальной гипертензией // Бюл. ВСНЦ СО РАМН. - 2012. - № 2-2 (84). - С. 26-29

3. Долгих В.В., Леонтьева И.В., Рычкова Л.В., Погодина А.В., Мандзяк Т.В., Бугун О.В., Поляков В.М. Алгоритмы диагностики и лечения, принципы профилактики артериальной гипертензии у подростков. -Иркутск: ООО «Аспринт», 2008. - 26 с

4. Житникова Л.М. Ацетилсалициловая кислота в профилактике и лечении сердечно-сосудистых заболеваний: клинические рекомендации для практикующих врачей / / Русский медицинский журнал. 2012. - № 14. - С. 708-714

5. Колесникова Л.И., Долгих В.В., Поляков В.М., Рычкова Л.В. Проблемы психосоматической патологии детского возраста. - Новосибирск: Наука, 2005. - 221 c

6. Михалевич И.М., Алферова М.А., Рожкова Н.Ю. Основы прикладной статистики: учебное пособие. -Иркутск: РИО ИГИУВа, 2008. - 71 c

7. Погодина А.В., Долгих В.В., Рычкова Л.В. Мочевая кислота и факторы кардиометаболического риска при артериальной гипертензии у подростков // Кардиология. - 2014. - Т. 54, № 7. - С. 36-42

8. Gaeta M, Campanella F, Gentile L, Schifino G.M, Capasso L, Bandera F, Banfi G, Arpesella M, Ricci C. (2017). European cardiovascular mortality over the last three decades: evaluation of time trends, forecasts for 2016. Ann Ig., May-Jun., 29 (3), 206-217.

9. Isordia-Salas I, Mendoza-Valdez A.L, Almei-da-Gutiérrez E, Borrayo-Sanchez G. (2010). Genetic factors of the hemostatic system in young patients with myocardial infarction. Cir., 78 (1), 93-97.

10. Kunnas T, Solakivi T, Määttä K, Nikkari S.T. (2016). Glucuronic acid epimerase (GLCE) variant rs3865014 (A>G) is associated with BMI, blood hemoglobin, hypertension, and cerebrovascular events, the TAMRISK Study. Ann. Hum. Genet., 80 (6), 332-335.

11. Ozturk M.T, Ebinç F.A, Okyay G.U, Kutlugün A.A. (2017). Epicardial adiposity is associated with microalbuminuria in patients with essential hypertension. Acta Cardiol. Sin., 33 (1), 74-80.

12. Sepülveda C, Palomo I, Fuentes E. (2017). Anti-platelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention. Vascul. Pharmacol., 1537-1891 (16), 30288-30289.